Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Best Practices Reports | Medical Affairs Resources, Structures and Trends

Medical Affairs Resources, Structures and Trends

This study explores how U.S. and global biopharmaceutical companies are structuring and managing their Medical Affairs organizations today. This study also examines recent trends in budget and staffing resources, key challenges and top success factors for the function. Pharmaceutical, biotech, and medical device managers and executives will be able to use this research to determine how their Medical Affairs organizations compare with industry benchmarks.

STUDY OVERVIEW Charged with building and maintaining physician relationships, pharmaceutical Medical Affairs organizations typically oversee several important functions – including publications, KOL programs, grants, and medical education (CME) that have been impacted in recent years by a call for increased transparency. As such, forward-looking biopharmaceutical executives are beginning to evaluate Medical Affairs operations to ensure that the vital organization is appropriately structured and resourced to operate effectively in the current environment.This Best Practices, LLC study explores how U.S. and global biopharmaceutical companies are structuring and managing their Medical Affairs organizations today. The study also examines recent trends in budget and staffing resources, key challenges and top success factors for the function. Pharmaceutical, biotech and medical device managers and executives will be able to use this research to determine how their Medical Affairs organizations compare with industry benchmarks.

KEY TOPICS - Organizational Structure- Reporting Relationship- Job Level of Group Leader- Geographic Span- Budget Allocation by Medical Affairs Function- Percent of Budget Allocated for Outsourcing- Recent and Anticipated changes in Resource Levels- Impact of Medical Affairs Functions on Company Success- Key Success Factors for Medical Affairs- Key Challenges for Medical Affairs

KEY METRICS - Type of structure (centralization)- Medical Affairs group dedication- Departmental reporting relationships- Job level or Medical Affairs head- Geographic span of organization- Percentage of spending per Medical Affairs function- Directional trends in staffing levels- Reasons cited for budget/staff increases- Reasons cited for budget/staff decreases- Relative importance of seven different Medical Affairs functions- Reasons cited for increased importance- Reasons cited for decreased importance- Percentage of budget allocated for outsourcing- Percent of companies impacted by FDA Revitalization Act- Top three success factors for developing and maintaining effective Medical Affairs group- Top three challenges for developing and maintaining effective Medical Affairs group

METHODOLOGY The research involved an online survey of 26 Medical Affairs at 25 leading pharmaceutical, biotechnology and medical device companies

INDUSTRIES PROFILED Biotech; Pharmaceutical; Consumer Products; Diagnostic; Manufacturing; Health Care

COMPANIES PROFILED Amgen; Astellas; AstraZeneca Pharmaceuticals; Bayer Schering AG; Bayer; Auxillium; Becton Dickinson; Bristol-Myers Squibb; Cubist Pharmaceuticals; Esteve; Genentech; Johnson & Johnson; Myriad; Novartis; Novo Nordisk; Pfizer; Schering-Plough; Solvay Pharmaceuticals; Vertex Pharmaceuticals; ApoPharma; OctoPlus; Procaps; Savient; SK&F; Werrick

August 2009 Pages 45 Format PDF
Table of Contents
Table of Contents (PDF)
Price: $4,100.00 / €2,715.43

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions